Shenzhou Cell is an innovative biopharmaceutical research and development company founded by Dr. Xie Liangzhi, an internationally renowned expert in biopharmaceutical R&D and industrialization. The company, listed in China with stock code 688520, focuses on the research and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins, and vaccines.

Shenzhou Cell is dedicated to various disease areas, including COVID-19, cervical cancer, hemophilia, malignant tumors, and autoimmune diseases. They have developed a recombinant 14-valent HPV vaccine that covers 12 high-risk carcinogenic HPV virus types and 2 main types causing genital warts, with an expected preventive protection rate of 96% against cervical cancer. Their product pipeline includes several other innovative drugs and biologics for the treatment of diseases mentioned earlier.

With a strong research capability, Shenzhou Cell is recruiting patients for their clinical trials, offering a range of protein drugs, antibody drugs, and genetic engineering vaccines for conditions such as tumors, autoimmune diseases, genetic diseases, and infectious diseases. For more information, please visit their website